Taiwan FDA registration 20a5599c0bbac4394483f6d14ba4c543
"100 first" angioconstrictin I radioimmunoassay reagent
TW: “百首” 血管收縮素I放射免疫分析試劑
Taiwan·Risk Class 2·DIASOURCE IMMUNOASSAYS S.A.·Registered Aug 17, 2020 – Aug 17, 2025ExpiredRegistration details
- Analysis ID
- 20a5599c0bbac4394483f6d14ba4c543
- Customs Code
- DHA05603352802
Company information
- Manufacturer
- DIASOURCE IMMUNOASSAYS S.A.
- Manufacturer Country
- Belgium
- Authorized Representative
- TAIWAN LIFE SUPPORT SYSTEMS INC.
Product details
- Intended Use
- This product uses radioimmunoassay to quantitatively detect the content of angioconin I and plasma renin activity in human EDTA plasma in vitro.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A.1085 Angioconstrictin I and renin test system
- Import Information
- Input;; QMS/QSD
Dates and status
- Registration Date
- Aug 17, 2020
- Expiry Date
- Aug 17, 2025
About this record
Access comprehensive regulatory information for "100 first" angioconstrictin I radioimmunoassay reagent in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number 20a5599c0bbac4394483f6d14ba4c543 and manufactured by DIASOURCE IMMUNOASSAYS S.A.. The authorized representative in Taiwan is TAIWAN LIFE SUPPORT SYSTEMS INC..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices